We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · May 29, 2020

Pemetrexed Plus Cisplatin vs Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous NSCLC

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer
J. Clin. Oncol 2020 May 14;[EPub Ahead of Print], H Kenmotsu, N Yamamoto, T Yamanaka, K Yoshiya, T Takahashi, T Ueno, K Goto, H Daga, N Ikeda, K Sugio, T Seto, S Toyooka, H Date, T Mitsudomi, I Okamoto, K Yokoi, H Saka, H Okamoto, Y Takiguchi, M Tsuboi

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading